EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose

Roger Crystal, Mark Ellison, Charlotte Purdon, Phil Skolnick

Clinical Pharmacology in Drug Development · 2024-01 · 13 (1) · 58-69

DOI: 10.1002/cpdd.1312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 27.07.2023. Verfasst von Roger Crystal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Indivior, Inc., North Chesterfield, VA, USA. Hauptthemen laut MEDLINE: Opiate Overdose, Drug Overdose. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nalmefene is a high‐affinity, long‐duration opioid antagonist that was approved in 1995 as an injection for the treatment of opiate overdose, but subsequently withdrawn (2008) for reasons other than safety or effectiveness. The dramatic rise in opioid overdose deaths over the past 7‐8 years catalyzed the development of an intranasal (IN) formulation of nalmefene for the emergency treatment of opioid overdose. The studies described here compare the pharmacokinetic properties and safety profiles of an IN formulation containing nalmefene (2.7 mg in 0.1 mL) to an approved 1 mg intramuscular (IM) dose. IN nalmefene produced maximum plasma concentrations that were significantly higher than observed following the IM dose (12.2 and 1.77 ng/mL, respectively). The time to reach maximum plasma concentrations was also faster following IN administration (0.25 and 0.33 hours, respectively) with significant differences in plasma concentrations manifested as early as 2.5 minutes after administration (NCT04759768). The plasma half‐life of nalmefene was similar following IM and IN administration (10.6‐11.4 hours). Furthermore, dose‐normalized nalmefene exposure was similar for both 1 spray in each nostril and 2 sprays in the same nostril compared to a single spray in each nostril (NCT05219669). There were no sex differences in the pharmacokinetic properties of either IN or IM nalmefene. In an era when almost 90% of opioid overdose deaths have been linked to high‐potency synthetic opioids, the ability to rapidly deliver high concentrations of nalmefene could represent an important tool for reducing both morbidity and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opiate OverdoseDrug OverdoseHumansNaltrexoneNarcotic Antagonists

Stichwörter der Autor:innen

dodecylmaltosideintranasalnalmefeneopioid overdosepharmacokinetics

Substanzen

nalmefeneNaltrexoneNarcotic Antagonists

Autor:innen und Institutionen

  • Indivior, Inc., North Chesterfield, VA, USA.

Förderung

  • NIDA NIH HHS

Zitieren

APA

Crystal, R., Ellison, M., Purdon, C., & Skolnick, P. (2024). Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose. Clinical Pharmacology in Drug Development, 13(1), 58-69. https://doi.org/10.1002/cpdd.1312

Vancouver

Crystal R, Ellison M, Purdon C, Skolnick P. Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose. Clinical Pharmacology in Drug Development. 2024;13(1):58-69. doi:10.1002/cpdd.1312

BibTeX
@article{Crystal2024,
  author = {Crystal, Roger and Ellison, Mark and Purdon, Charlotte and Skolnick, Phil},
  title = {Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  volume = {13},
  number = {1},
  pages = {58--69},
  doi = {10.1002/cpdd.1312}
}
Kostenlos starten →